Status:
COMPLETED
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
Lead Sponsor:
Bayer
Conditions:
Primary Hypertension
Eligibility:
All Genders
18-65 years
Brief Summary
The purpose of this study is to demonstrate the safety and efficacy of inhaled Iloprost (Ventavis®) among adult Chinese patients with primary pulmonary hypertension, which is in compliance with Chines...
Eligibility Criteria
Inclusion
- Both male and female age 18-65 years old
- The treating physician has chosen Ventavis as a suitable long-term treatment for the patient
- Patient with Primary Pulmonary Hypertension (i.e. IPAH or FPAH) and classified as NYHA functional class III
- Written informed/data protection consent
- No prior treatment with Ventavis or other active treatments for PPH within 6 weeks of date of study.
Exclusion
- Known or newly identified contraindication for administration of Ventavis as stated in the Ventavis product package insert.
Key Trial Info
Start Date :
February 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00882947
Start Date
February 1 2006
End Date
September 1 2008
Last Update
April 17 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, China